Targeted therapy of kidney cancer: Keeping the art around the algorithms

Cancer Control

Volumn 20, Issue 3, 2013, Pages 222-232

  Fishman, Mayer N ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; DOVITINIB; EVEROLIMUS; GIRENTUXIMAB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLACEBO; RAPAMYCIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; VITESPEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CAPILLARY LEAK SYNDROME; CHILL; CLINICAL TRIAL (TOPIC); COMORBIDITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GRAFT REJECTION; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; METASTASIS RESECTION; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ALGORITHM; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; METABOLISM; MULTIMODALITY CANCER THERAPY; PROGNOSIS;

ALGORITHMS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; PROGNOSIS;

EID: 84879508487     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481302000310     Document Type: Article

References (78)

1. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530-2540.
2. Manola J, Royston P, Elson P, et al; International Kidney Cancer Working Group. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Cancer Res. 2011;17(16):5443-5450.
3. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-3590.
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312-3318.
5. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137-2143.
6. Escudier B, Pluzanska A, Koralewski P, et al; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-2111.
7. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-1068.
8. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287-1296.
9. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-1939.
10. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552-562.
11. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281.
12. Motzer RJ, Escudier B, Oudard S, et al; RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-4265.
13. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21(16):3127-3132.
14. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133-141.
15. AVEO and Astellas announce tivozanib successfully demonstrated progression-free survival superiority over sorafenib in patients with advanced renal cell cancer in phase 3 TIVO-1 trial [press release]. http://investor.aveopharma.com/External.File?t=2&item=g7rqBLVLuv81UAmrh20MpxvqqtIs5C/D8BsXc-WcNodsqVAF7fGnB4UHpyZ0U/WtbmYCHwP5tGx06WJH7-xsEUcw==. Accessed February 6, 2013.
16. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial. J Clin Oncol. 2012;30(suppl):4501.
17. AVEO and Astellas report final overall survival results from TIVO-1 [manufacturer press release]. http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&id=1784461. Accessed May 28, 2013.
18. Pfizer provides topline results from phase 3 study of Torisel as second-line treatment in advanced renal cell carcinoma (RCC) [press release]. http://www.drugs.com/clinicaltrials/pfizer-provides-topline-results-phase-3-study-torisel-second-line-advanced-renal-cell-carcinoma-rcc-13531.html Accessed February 6, 2013.
19. www.clinicaltrials.gov/ct2/show/NCT01223027. Accessed May 28, 2013.
20. www.clinicaltrials.gov/ct2/show/NCT01481870. Accessed May 28, 2013.
21. www.clinicaltrials.gov/ct2/show/NCT00732914. Accessed May 28, 2013.
22. Stenner F, Chastonay R, Liewen H, et al. A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Oncology. 2012;82(6):333-340.
23. Motzer R, Hutson TE, Reeves J, et al. Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC): results of the COMPARZ trial. Abstract presented at: 37th ESMO Conference; September 2012; Vienna, Austria. Abstract 2325. http://abstracts.webges.com/viewing/view.php?congress =esmo2012&congress_id=370&publication_id=2325. Accessed June 2, 2013.
24. www.clinicaltrials.gov/ct2/show/NCT00903175. Accessed May 28, 2013.
25. Motzer RJ, Barrios CH, Kim TM, et al. Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2013;31(suppl):4504. Abstract. http://meetinglibrary.asco.org/print/1161631. Accessed June 13, 2013.
26. www.clinicaltrials.gov/ct2/show/NCT01265901. Accessed May 28, 2013.
27. www.clinicaltrials.gov/ct2/show/NCT00930033. Accessed May 28, 2013.
28. www.clinicaltrials.gov/ct2/show/NCT01099423. Accessed May 28, 2013.
29. www.clinicaltrials.gov/ct2/show/NCT00087022. Accessed May 28, 2013.
30. http://www.wilex.de/press-investors/announcements/press-releases/20121016-2/. Accessed May 28, 2013.
31. www.clinicaltrials.gov/ct2/show/NCT00326898. Accessed May 28, 2013.
32. www.clinicaltrials.gov/ct2/show/NCT01235962. Accessed May 28, 2013.
33. www.clinicaltrials.gov/ct2/show/NCT01120249. Accessed May 28, 2013.
34. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372(9633):145-154.
35. Singer EA, Gupta GN, Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol. 2012;24(3): 284-290.
36. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011;108(10):1556-1563.
37. Motzer RJ, Agarwal N, Beard C, et al. Kidney cancer. J Natl Compr Canc Netw. 2011;9(9):960-977.
38. Romo de Vivar Chavez A, de Vera ME, Liang X, et al. The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma. Med Oncol. 2009;26(suppl 1):3-12.
39. Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer: when TKIs are not enough. Nat Rev Clin Oncol. 2009;6(8):478-487.
40. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
41. Pópulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13(2):1886-1918.
42. Cho DC, Cohen MB, Panka DJ, et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res. 2010;16(14):3628-2638.
43. Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int. 2009;104(11):1585-1589.
44. Négrier S, Gravis G, Pérol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011;12(7):673-680.
45. Kabbinavar FF, Srinivas S, Hauke RJ, et al. Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC). J Clin Oncol. 2011;29(suppl);4549.
46. Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep. 2011;13(2):103-111.
47. Gupta S, Fishman M. Progress and contrasts of the development of tivozanib for therapy of kidney cancer. Expert Opin Pharmacother. 2011; 12(18):2915-2922.
48. www.clinicaltrials.gov/ct2/show/NCT01358721. Accessed May 28, 2013.
49. Bellmunt J, Eisen T, Fishman M, et al. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011;78(1):24-32.
50. Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012;104(2):93-113.
51. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071-1076.
52. Collins S, Pierorazio PM, McKiernan JM, et al. Fractional percentage of tumor volume removed is a predictor of outcome following cytoreductive nephrectomy for metastatic renal cell carcinoma. J Clin Oncol. 2006;24(18 suppl):4599.
53. Barbastefano J, Garcia JA, Elson P, et al. Association of percentage of tumor burden removed with debulking nephrectomy and progression free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients (Pts) treated with VEGF-targeted therapy. J Clin Oncol. 2009;27(15 suppl);5095.
54. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60-66.
55. Bratslavsky G. Argument in favor of performing partial nephrectomy for tumors greater than 7 cm: the metastatic prescription has already been written. Urol Oncol. 2011;29(6):829-832.
56. Spiess PE, Kurian T, Lin HY, et al. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients under-going nephrectomy and inferior vena cava thrombectomy. BJU Int. 2012;110 (11 pt B):E470-E474.
57. Tan HJ, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC. Long-term survival following partial vs radical nephrectomy among older patients with earlystage kidney cancer. JAMA. 2012;307(15):1629-1635.
58. Antonelli A, Ficarra V, Bertini R, et al. Elective partial nephrectomy is equivalent to radical nephrectomy in patients with clinical T1 renal cell carcinoma: results of a retrospective, comparative, multi-institutional study. BJU Int. 2012;109(7):1013-1018.
59. Spiess PE, Fishman MN. Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma. Cancer Control. 2010;17(4):269-278.
60. Rini BI, Garcia J, Elson P, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol. 2012;187(5): 1548-1554.
61. Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(25):4076-4081.
62. Abel EJ, Culp SH, Tannir NM, et al. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol. 2011;60(6):1273-1279.
63. Gorin MA, Ekwenna O, Soloway MS, et al. Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery. Urology. 2012;79(2):e11.
64. Ansari J, Doherty A, McCafferty I, et al. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma. Clin Genitourin Cancer. 2009;7(2):E39-E41.
65. Canter D, Kutikov A, Sirohi M, et al. Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology. 2011; 77(4):781-785.
66. Daliani DD, Tannir NM, Papandreou CN, et al. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int. 2009;104(4):456-460.
67. Karam JA, Rini BI, Varella L, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011;185(2):439-444.
68. Hanson PW, Elaimy AL, Lamoreaux WT, et al. A concise review of the efficacy of stereotactic radiosurgery in the management of melanoma and renal cell carcinoma brain metastases. World J Surg Oncol. 2012;10:176.
69. Noel G, Valery CA, Boisserie G, et al. LINAC radiosurgery for brain metastasis of renal cell carcinoma. Urol Oncol. 2004;22(1):25-31.
70. Henderson CA, Bukowski RM, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: subset analysis of patients (pts) with brain metastases (BM). J Clin Oncol. 2007;25(suppl 18S): 15506.
71. Hariharan S, Szczylik C, Porta C, et al. Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial. J Clin Oncol. 2008;26(suppl):5094.
72. Chevreau C, Ravaud A, Escudier B, et al. Phase II trial of sunitinib in renal cell cancer with untreated brain metastases. J Clin Oncol. 2011;29(suppl):4625.
73. Bracarda S, Bellmunt J, Melichar B, et al. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int. 2011;107(2):214-219.
74. Masini C, Sabbatini R, Porta C, et al. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int. 2012;110(5):692-698.
75. Josephs D, Hutson TE, Cowey CL, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int. 2011;108(8):1279-1283.
76. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gas-trointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25(13):1753-1759.
77. Krajewski KM, Guo M, Van den Abbeele AD, et al. Comparison of four early post-therapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011;59(5):856-862.
78. Cho DC, Puzanov I, Regan MM, et al. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. Immunother. 2009;32(2):181-185.